Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017757358> ?p ?o ?g. }
- W2017757358 endingPage "1187" @default.
- W2017757358 startingPage "1170" @default.
- W2017757358 abstract "Crizotinib (1), an anaplastic lymphoma kinase (ALK) receptor tyrosine kinase inhibitor approved by the U.S. Food and Drug Administration in 2011, is efficacious in ALK and ROS positive patients. Under pressure of crizotinib treatment, point mutations arise in the kinase domain of ALK, resulting in resistance and progressive disease. The successful application of both structure-based and lipophilic-efficiency-focused drug design resulted in aminopyridine 8e, which was potent across a broad panel of engineered ALK mutant cell lines and showed suitable preclinical pharmacokinetics and robust tumor growth inhibition in a crizotinib-resistant cell line (H3122-L1196M)." @default.
- W2017757358 created "2016-06-24" @default.
- W2017757358 creator A5000804175 @default.
- W2017757358 creator A5004738391 @default.
- W2017757358 creator A5005961506 @default.
- W2017757358 creator A5006108649 @default.
- W2017757358 creator A5006518535 @default.
- W2017757358 creator A5007561793 @default.
- W2017757358 creator A5013275215 @default.
- W2017757358 creator A5016261016 @default.
- W2017757358 creator A5016477511 @default.
- W2017757358 creator A5018010707 @default.
- W2017757358 creator A5018283590 @default.
- W2017757358 creator A5023150983 @default.
- W2017757358 creator A5023840148 @default.
- W2017757358 creator A5024884642 @default.
- W2017757358 creator A5031081898 @default.
- W2017757358 creator A5031608383 @default.
- W2017757358 creator A5031922271 @default.
- W2017757358 creator A5034433068 @default.
- W2017757358 creator A5036437571 @default.
- W2017757358 creator A5037825633 @default.
- W2017757358 creator A5039232586 @default.
- W2017757358 creator A5044435389 @default.
- W2017757358 creator A5045007590 @default.
- W2017757358 creator A5046375198 @default.
- W2017757358 creator A5052326591 @default.
- W2017757358 creator A5056520253 @default.
- W2017757358 creator A5057138271 @default.
- W2017757358 creator A5058836905 @default.
- W2017757358 creator A5059826923 @default.
- W2017757358 creator A5066503615 @default.
- W2017757358 creator A5071037763 @default.
- W2017757358 creator A5072025067 @default.
- W2017757358 creator A5074829279 @default.
- W2017757358 creator A5074891065 @default.
- W2017757358 creator A5074985510 @default.
- W2017757358 creator A5077699282 @default.
- W2017757358 creator A5081248990 @default.
- W2017757358 creator A5082616184 @default.
- W2017757358 creator A5083705936 @default.
- W2017757358 creator A5085891569 @default.
- W2017757358 creator A5090366405 @default.
- W2017757358 date "2014-02-06" @default.
- W2017757358 modified "2023-10-18" @default.
- W2017757358 title "Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib" @default.
- W2017757358 cites W1719751125 @default.
- W2017757358 cites W1969406069 @default.
- W2017757358 cites W1970822548 @default.
- W2017757358 cites W1976851503 @default.
- W2017757358 cites W1988137261 @default.
- W2017757358 cites W1997476230 @default.
- W2017757358 cites W1998371249 @default.
- W2017757358 cites W2010978319 @default.
- W2017757358 cites W2014639631 @default.
- W2017757358 cites W2020666187 @default.
- W2017757358 cites W2022354436 @default.
- W2017757358 cites W2025718938 @default.
- W2017757358 cites W2026002143 @default.
- W2017757358 cites W2027179985 @default.
- W2017757358 cites W2031196045 @default.
- W2017757358 cites W2031942559 @default.
- W2017757358 cites W2035282066 @default.
- W2017757358 cites W2037930459 @default.
- W2017757358 cites W2038056960 @default.
- W2017757358 cites W2038586807 @default.
- W2017757358 cites W2044558623 @default.
- W2017757358 cites W2049643200 @default.
- W2017757358 cites W2055402151 @default.
- W2017757358 cites W2060275730 @default.
- W2017757358 cites W2061278019 @default.
- W2017757358 cites W2066417528 @default.
- W2017757358 cites W2075131732 @default.
- W2017757358 cites W2080992857 @default.
- W2017757358 cites W2096156234 @default.
- W2017757358 cites W2097757428 @default.
- W2017757358 cites W2111254482 @default.
- W2017757358 cites W2113327188 @default.
- W2017757358 cites W2113701650 @default.
- W2017757358 cites W2122800348 @default.
- W2017757358 cites W2124478432 @default.
- W2017757358 cites W2133668831 @default.
- W2017757358 cites W2140333474 @default.
- W2017757358 cites W2145934373 @default.
- W2017757358 cites W2150424194 @default.
- W2017757358 cites W2161650275 @default.
- W2017757358 cites W2170144893 @default.
- W2017757358 cites W2953011238 @default.
- W2017757358 cites W4230962467 @default.
- W2017757358 doi "https://doi.org/10.1021/jm401805h" @default.
- W2017757358 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24432909" @default.
- W2017757358 hasPublicationYear "2014" @default.
- W2017757358 type Work @default.
- W2017757358 sameAs 2017757358 @default.
- W2017757358 citedByCount "93" @default.
- W2017757358 countsByYear W20177573582014 @default.
- W2017757358 countsByYear W20177573582015 @default.
- W2017757358 countsByYear W20177573582016 @default.